Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study

Impact of age and comorbidities on real-world outcomes in advanced breast cancer patients treated with palbociclib in first line: a nation-wide Danish retrospective study

Background and purpose: Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, combined with aromatase inhibitors (AI), can be used in first-line treatment for estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) normal advanced breast cancer (ABC). This study aim...

Full description

Saved in:
Bibliographic Details
Main Authors: Alan Celik, Laurits Sebastian Dahl, Rasmus Garly, Vesna Glavicic, Maja Bendtsen Sharma, Sophie Yammeni, Humma Khan, Daniel Sloth Hauberg, Hanne Schultz Kapel, Ann Knoop, Tobias Berg
Format: Article
Language:English
Published: Medical Journals Sweden 2025-06-01
Series:Acta Oncologica
Subjects:
Advanced Breast Cancer
Palbociclib
CDK4/6 inhibitor
survival
age
comorbidity
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/43226
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://medicaljournalssweden.se/actaoncologica/article/view/43226

Similar Items